ClinicalTrials.gg
RecruitingNCT07456657LAM-RAUpdated Sep 16, 2026

Effect of Lavender Aromatherapy Massage on Pain and Wrist Mobility in Rheumatoid Arthritis

An interventional study of Lavender Aromatherapy Massage and Inert Almond Oil Massage in Rheumatoid Arthritis (RA), sponsored by University of Baghdad. Recruiting at 1 site in Iraq. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Baghdad · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effect of lavender aromatherapy massage on pain intensity and wrist joint mobility in patients with rheumatoid arthritis. Participants will be randomly assigned to receive lavender aromatherapy massage in addition to standard care or standard care alone. Pain intensity and wrist mobility will be measured before and after the intervention period. The findings of this study may provide evidence regarding the effectiveness of complementary therapies in reducing pain and improving joint function in patients with rheumatoid arthritis.

Read the detailed description

Rheumatoid arthritis is a chronic autoimmune inflammatory disease characterized by joint pain, stiffness, and reduced mobility, particularly affecting small joints such as the wrist. Despite pharmacological treatments, many patients continue to experience persistent pain and functional limitations.

Lavender aromatherapy massage is considered a complementary therapy that may help reduce pain and improve circulation and joint flexibility through both mechanical stimulation and the therapeutic properties of lavender essential oil.

This study is designed as a randomized controlled trial to examine the effect of lavender aromatherapy massage on pain intensity and wrist joint mobility in patients diagnosed with rheumatoid arthritis. Eligible participants will be randomly assigned into two groups: an intervention group receiving lavender aromatherapy massage in addition to routine medical care, and a control group receiving routine medical care only.

Pain intensity will be assessed using a standardized pain scale, and wrist joint mobility will be measured using appropriate clinical assessment tools before and after the intervention period.

The results of this study may contribute to evidence-based practice by determining whether lavender aromatherapy massage can be recommended as a safe and effective complementary intervention for managing pain and improving joint mobility in patients with rheumatoid arthritis.

02

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Lavender Aromatherapy
  • Massage Therapy
  • Wrist Mobility
  • Pain
  • Rheumatoid Arthritis
03

In context

Arthritis, Rheumatoid

3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.

This study's planned enrollment of 120 is above the median of 96 across 2,220 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

University of Baghdad is the lead sponsor of 170 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20 to 60 years
  • Diagnosis of rheumatoid arthritis meeting the 2010 ACR/EULAR classification criteria
  • Seropositive for Rheumatoid Factor (RF)
  • Stable dosage of RA medications (NSAIDs, csDMARDs, bDMARDs) for at least 3 months prior to enrollment with commitment to maintain the regimen

Exclusion criteria

Exclusion Criteria:

  • Acute joint inflammation or infection in the hands or upper back during screening
  • Recent surgery (within 6 months) affecting hands or upper back
  • Dermal lesions, open wounds, infections, or significant vascular pathology at treatment sites
  • Serious comorbidities (uncontrolled diabetes, renal failure, cancer, severe cardiac/respiratory disease, coagulopathies, anticoagulant use)
  • Pregnancy or breastfeeding
  • Previous lavender aromatherapy massage within 6 months
  • Documented to lavender aromatherapy massage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Lavender Aromatherapy Massage Group

    Participants will receive lavender aromatherapy massage . The massage will be applied using lavender essential oil according to the study protocol , twice weekly

    Other: Lavender Aromatherapy Massage

  • Placebo comparator
    Inert Almond Oil (Placebo Massage)

    Participants in this group will receive massage using inert almond oil without lavender essential oil according to the same duration , twice weekly and procedure as the experimental group .This serves as a placebo control to maintain participant blinding.

    Other: Inert Almond Oil Massage

Interventions

  • OtherLavender Aromatherapy Massage

    Massage therapy using lavender essential oil applied to the wrist according to the study protocol , twice weekly.

  • OtherInert Almond Oil Massage

    Massage using inert almond oil without lavender essential oil, applied with the same duration and procedure as the experimental group , twice weekly.

06

What researchers measure

Primary outcomes

  1. Pain Intensity

    Pain intensity will be measured using the Visual Analog Scale (VAS). The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. Higher scores indicate greater pain intensity.

    Time frame: Baseline and after completion of the intervention period (e.g., 4 weeks).

Secondary outcomes

  1. Wrist Joint Mobility

    Wrist joint mobility will be assessed using a goniometer.

    Time frame: Baseline and after completion of the intervention period (e.g., 4 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to privacy and confidentiality considerations and institutional regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 292 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456657
Responsible party
Ethar Haider Fadhil (PhD Student, College of Nursing, University of Baghdad, University of Baghdad) — Principal investigator
First posted
Mar 6, 2026
Start date
Apr 1, 2026
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Ethar Haider Fadhil, PhD Candidate
Contact
ethar.najm2102m@conursing.uobaghdad.edu.iq
+9647810626779
Serwan Jafar Bakey, Phd
principal investigator · University of Baghdad, College of Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion